Novan Therapeutics appointed two new executives from the dermatology industry to the company's leadership team. Richard Peterson has joined the company as Chief Financial Officer and Brian Johnson as Chief Commercial Officer. Mr. Peterson will be responsible for the company's financial operations, investor relations, and other corporate functions. Mr. Johnson will lead Novan's newly focused commercialization efforts including sales, marketing and managed care for the company's dermatology products. 

Richard Peterson joins Novan after a nearly 20-year career at Medicis Pharmaceutical Corporation where he held roles in finance, accounting and business development.  Most recently, Mr. Peterson served as Executive Vice President, Chief Financial Officer and Treasurer of the NYSE-traded company until its acquisition in 2012 by Valeant Pharmaceuticals International for $2.6 billion.  During his time at Medicis, the company achieved tremendous growth in revenue and profitability with a suite of products including Solodyn®. Prior to joining Medicis, Mr. Peterson was a senior financial auditor with PricewaterhouseCoopers.  He currently serves as a Director at Universal Insurance Holdings, Incorporated.

Brian Johnson brings to Novan nearly three decades of marketing and sales leadership at dermatology companies including Ortho Pharmaceutical Corporation (Johnson & Johnson's Dermatological Division), Medicis Pharmaceutical Corporation and Galderma Laboratories, LLC where he served as Vice President of Prescription Marketing and Chief Digital Officer.  At Galderma, he and his team quadrupled sales by launching products, including Epiduo®, Clobex®, and Oracea®. In addition to Epiduo®, throughout his career he participated in the sales and/or marketing of several other acne brands including Retin-A®, Dynacin®, and Differin®.